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Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is
unclear whether the presence of these arrhythmias has therapeutic consequences. We sought to summarize evidence on the prevalence
of atrial high-rate episodes (AHREs) and their impact on risk of stroke. We performed a comprehensive, tabulated review of published
literature on the prevalence of AHRE. In patients with AHRE, but without atrial fibrillation (AF), we reviewed the stroke risk and the
potential risk/benefit of oral anticoagulation. Atrial high-rate episodes are found in 10–30% of AF-free patients. Presence of AHRE slightly
increases stroke risk (0.8% to 1%/year) compared with patients without AHRE. Atrial high-rate episode of longer duration (e.g. those
>24 h) could be associated with a higher stroke risk. Oral anticoagulation has the potential to reduce stroke risk in patients with AHRE
but is associated with a rate of major bleeding of 2%/year. Oral anticoagulation is not effective in patients with heart failure or survivors of
a stroke without AF. It remains unclear whether anticoagulation is effective and safe in patients with AHRE. Atrial high-rate episodes
are common and confer a slight increase in stroke risk. There is true equipoise on the best way to reduce stroke risk in patients with
AHRE. Two ongoing trials (NOAH-AFNET 6 and ARTESiA) will provide much-needed information on the effectiveness and safety of oral
anticoagulation using non-vitamin K antagonist oral anticoagulants in patients with AHRE.
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Introduction
The increased use of cardiac implantable electronic devices (CIED)
and their technical ability to monitor atrial rhythm and to identify
even very short episodes of atrial arrhythmias has transformed our
understanding of these events in the last 10–15 years. Having an atrial
lead implanted, CIED can detect episodes of atrial tachyarrhythmias
including atrial tachycardia, atrial flutter, and atrial fibrillation (AF).
These episodes, which are commonly asymptomatic and only
detected through long-term continuous rhythm monitoring by a
CIED, are described as atrial high-rate episodes (AHREs) and must
be distinguished from asymptomatic episodes of paroxysmal AF,
which are diagnosed through surface electrocardiographic meth-
ods1–4: Some AHRE do not represent true atrial tachyarrhythmias,
but reflect artefacts.5 In addition, the biological relevance of very rare
AHRE, which will usually not be detected by occasional electrocar-
diograms (ECGs), remains unknown.
Here, we provide a comprehensive review of the prevalence of
AHRE, their impact on stroke risk and current implications for man-
agement. While other have used the term ‘sub-clinical AF’, we use
AHRE in this review, partially reflecting the diagnostic uncertainty,
the high prevalence of AHRE compared with ECG-documented AF,
and their spurious association with overt AF and with AF-related
outcomes.
Prevalence of atrial high-rate epi-
sodes in patients undergoing con-
tinuous atrial rhythmmonitoring
Atrial high-rate episodes have been reported in several large obser-
vational studies with different design, cohort size, patient characteris-
tics, duration of follow-up, detection algorithms, and definition of
AHRE in terms of atrial rate and duration (Table 1). Most of these
studies included unselected patients with common indications for
pacemaker or implantable cardioverter-defibrillator,6–15 while others
analysed populations with heart failure or risk factors for stroke.16–23
Most studies used an atrial rate limit of >175 or >180 to define an
AHRE,6,11,12,16–18,20 while a few others used atrial rates that were
even higher.7,19,21 Atrial high-rate episodes were reported in 10% in
the SAFE registry and in 70% in the analysis of data from the Veterans
Administration Health Care System (Table 1). Importantly, studies
including patients with the clinical diagnosis AF, which per se
have a higher frequency of atrial arrhythmias, found AHRE in 40–
70%.1,6–9,11,13,16,20,21,23 Studies excluding patients with known AF
have found AHRE in 10–30% of patients % (Figure 1).10,12,14,17–19,22
The minimal duration of AHRE varied from three premature atrial
complexes—much below the threshold for a sustained atrial arrhyth-
mia in the view of most experts—in the RATE Registry to up to
14 min in the pooled analysis from the HOME Care and EVEREST tri-
als,15,20 with the majority of studies using an episode duration longer
than 5–6 min to define AHRE.7,9,10,12,14,17–19,22,23 This duration seems
to be a ‘diagnostic sweet spot’ that allows most algorithms detecting
AHRE to distinguish artefacts from true atrial arrhythmias. This dura-
tion has not been selected based on biological relevance (e.g. associa-
tion with stroke risk). There is a clear relation between the detection
of AHRE and the duration of monitoring, e.g. illustrated in the
ASSERT trial that found AHRE in 10% of patients within the first
3 months after enrolment, and in an additional 24.5% during the sub-
sequent mean follow-up of 2.5 years.19,24
The high AHRE detection rates spurred discussion whether these
rates are generalizable, e.g. reflecting that these patients all had
arrhythmias requiring a CIED which may also create a substrate for
AHRE3,25 and potentially a proarrhythmic effect in the first few weeks
after implantation of a new atrial lead.12,26 Several studies using sub-
cutaneous implantable loop recorders (ILRs) have largely refuted
these considerations, at least in patients with stroke risk factors.
These devices detect QRS complexes and determine AHRE using
similar algorithms based on ventricular rate and its regularity.27,28
Implantation of an ILR in stroke survivors, often after usual work-up
for AF including Holter monitoring, found AHRE in 4–34% of
patients, depending on monitoring duration and patient characteris-
tics (Table 2).29–40 Implantable loop recorders also detect AHREs in
21–58% of patients with cardiovascular conditions, but without an in-
dication for rhythm monitoring (Table 3),41–45 i.e. with comparable
rates as in pacemaker populations. Thus, these data suggest that
AHRE are common in patients with cardiovascular conditions under-
going long-term continuous monitoring of atrial rhythm.
Patients with atrial fibrillation,
including those with paroxysmal
atrial fibrillation, are at sufficient
risk for cardioembolic stroke to
benefit from oral anticoagulation
for stroke prevention
Atrial fibrillation in rheumatic heart disease was recognized as a factor
that predisposes to systemic embolism in 1951.46 Left atrial emboli
causing ischaemic stroke were described a decade later.47 In the
Framingham Heart Study, AF was associated with a five-fold long-
term increased risk of stroke.48,49 Prospective randomized studies
from the late 1980s reported a dramatic and highly significant reduc-
tion in stroke in patients with AF treated with warfarin. The
randomized AFASAK,50 SPAF,51 and BAATAF52 studies were among
the first to demonstrate that dose-adjusted warfarin prevented
strokes effectively in patients with AF, confirmed in a later meta-
analysis.53
Until recently, the risk of thromboembolism has been considered
to be independent of AF type.54–57 Previous systematic reviews of
risk factors for stroke in AF patients have not identified AF type as an
important prognostic risk factor for thromboembolism.58–60 Atrial
fibrillation stroke risk prediction models have, in general, not included
AF type61–64 perhaps because of absence of AF pattern information
in hospitalization/discharge databases that were used for their deriva-
tion and validation. This consensus of risk equivalence between AF
patterns is reflected by Class I and IIa recommendations in current
European55 and North American54 guidelines.
Vanassche et al.65 pooled the data on aspirin-treated patients
(n= 6573) from the ACTIVE-A and AVERROES trials. Atrial
fibrillation pattern was a strong independent predictor of risk for
2 E. Bertaglia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/advance-article-abstract/doi/10.1093/europace/euz172/5543496 by B-O
n C
onsortium
 Portugal user on 08 August 2019
0%
AID
A (1
998
)
Gil
lis 
(20
02)
MO
ST
 (20
03)
Ts
e (2
005
)
Ca
pu
cci
 (20
05)
RA
TE
 Re
gis
try
 (20
16)
Ch
eu
ng
 (20
06)
SA
FE
 Re
gis
try
 (20
08)
Wi
tt (2
015
)
Go
nza
lez
 (20
14)
AS
SE
RT
 (20
12)
 FU
AS
SE
RT
 (20
12)
 3 m
o
TR
EN
DS
 (20
12)
TR
EN
DS
 (20
10)
Tu
rak
hia
 (20
15)
IM
PA
CT
 (20
15)
He
ale
y (2
013
)
Sh
an
mu
ga
m 
(20
12)
TR
EN
DS
 (20
09)
A-H
IRA
TE
 (20
07)
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Unselected Populations with Devices Patients without known AF
AHRE No AHRE
Figure1 Percentage of AHRE in patients with (left panel) and without (right panel) known AF. AF, atrial fibrillation; AHRE, atrial high-rate episode.
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Table 1 Incidence of CIED-detected AHRE
Study Number of
patients
Mean age
(years)
% male Duration of
follow-up
Definition of AHRE Patients with
AHRE
AIDA (1998) 617 70 ± 11 62% 28 days >_1 min (the AIDA
algorithm)
179/354 (50.6%)
Gillis et al. (2002) 231 70 ± 12 52% 718 ± 383 days Atrial rate >180 b.p.m.
for >_1 min; sustained
AF >250 b.p.m. for
>1 min
126/231 (54.5%) (AF)
MOST (2003) 312 74 45% Median 27 months Atrial rate >220 b.p.m.
for >5 min
160/312 (51.3%)
Tse et al. (2005) 226 72 ± 10 in patients
with detected
AF; 70 ± 10 in
patients without
detected AF
39% 84 ± 16 months Any AT detected by the
device
99/226 (43.8%)
Capucci et al.
(2005)
725 71 ± 11 50% Median 22 months
(16–30)
AF >5 min; AF >1 day 76.2%; 56.3%
Cheung et al.
(2006)
262 74 ± 12 54% 596 ± 344 days AHRE >_5 min 77/262 (29%)
A-HIRATE
(2007)
427 75 ± 9 56% 24 months Atrial rate >180 b.p.m.
for >_1 min
53.8% in patients
without previous
AT; 88.6% in
patients with pre-
vious AT
SAFE registry
(2008)
1482 74 ± 12 56% Median 349 ± 147
days
Atrial rate >_180 b.p.m.
for >_5 min
150/1482 (10.1%)
TRENDS (2009) 2486 71 ± 11 66.4% Median 1.4 years (0.1–
3.3)
Atrial rate >175 b.p.m.
for >_20 s
1389/2486 (55.9%)
Continued
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embolic event (ischaemic or unspecified stroke or systemic embo-
lism). The ACTIVE-W trial found a trend towards higher stroke (and
systemic embolism) rates in persistent/permanent compared with
paroxysmal AF in non-anticoagulated patients but not in warfarin-
treated patients.57 Similarly, the data from Friberg et al.66 did not
show a significant overall difference in stroke rates according to AF
pattern, but found an increase in ischaemic stroke in the subgroup of
non-anticoagulated patients with permanent compared with
....................................................................................................................................................................................................................
Table 1 Continued
Study Number of
patients
Mean age
(years)
% male Duration of
follow-up
Definition of AHRE Patients with
AHRE
TRENDS (2010) 163 74.0 ± 9.1 in
patients with
AHRE;
72.8 ± 9.9 in
patients without
AHRE
71.1% in patients
with AHRE;
62.7% in
patients without
AHRE
1.1 ± 0.7 years Atrial rate >175 b.p.m.
for >_5 min
45/163 (27.6%)
TRENDS (2012) 1368 70.2 ± 11.8 66.2% 1.1 ± 0.7 years Atrial rate >175 b.p.m.
for >_5 min
416/1368 (30.4%)
ASSERT (2012) 2580 77 ± 7 in patients
with AHRE;
76 ± 7 in
patients without
AHRE
56.3% in patients
with AHRE;
58.6% in
patients without
AHRE
Mean 2.5 years Atrial rate >_190 b.p.m.
for >6 min; all epi-
sodes confirmed by
manual expert review
of electrograms
261/2580 (10.1%)
within 3 months af-
ter device implan-
tation; 633/2566
(24.6%) during fur-
ther follow-up
Shanmugam et al.
(2012)
560 66 ± 10 77.4% Median 370 days
(253–390)
Atrial rate >180 b.p.m.
for >_14 min
223/560 (39.8%);
126/382 without
history of AF, 97/
178 with history of
AF
Healey et al.
(2013)
445 74.3 ± 13.7 in
patients with
AHRE;
71.7 ± 14.4 in
patients without
AHRE
58% in patients
with AHRE,
59% in patients
without AHRE
51.5 ± 39.7 months Any PM detected AF
(manufacturer-spe-
cific nominal settings
for AF detection)
246/445 (55.3%)
Gonzalez et al.
(2014)
224 74 ± 12 53% 6 months after PM
implantation
Any device-detected
AHRE >_5 min
39/224 (17.4%)
IMPACT (2015) 2718 Median 64.4 73.7% Median 701 days Atrial rate >_200 b.p.m.
for >_36 of 48 atrial
beats
945/2718 (34.8%)
Witt et al. (2015) 394 Median 67 years
(59–74)
74% Median 4.2 years (2.5–
6.6)
Manufacturer-specific
nominal settings for
AF detection; AHREs
>6 min
79/394 (20.0%)
Turakhia et al.
(2015)
187 68 ± 8.4 99.5% 120 days AF >_6 min 70.1% (26.2% >_6 min
of AF; 24.6% >_1 h
of AF; 19.3%
>_5.5 h of AF)
RATE Registry
(2016)
5379 73.6 ± 11.8 in
patients with
PM; 64.5 ± 12.6
in patients with
ICD
54.1% with PM;
72.4% with ICD
Median 22.9 months >_3 premature atrial
complexes
145/300 (48%) with
PM and 155/300
(52%) with ICD of
the representative
random sample
studied
AF, atrial fibrillation; AHRE, atrial high-rate episode; AT, atrial tachycardia; CIED, cardiac implantable electronic devices; ICD, implantable cardioverter-defibrillator;
PM, pacemaker.
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Table 2 Incidence of ILR-detected subclinical AF in patients with cryptogenic stroke or transient ischaemic attack
Study Number of
patients
included
Mean age
(years)
% male Mean CHA2DS2-
VASc score
Duration of
follow-up
Definition of
AHRE
Patients with
AHRE
Time to first
AHRE episode
Dion et al.
(2010)
24 49 ± 13.6 62.5% NR Mean 14.5 months Ventricular rate
>165 b.p.m. for
>32 complexes
1/24 (4.2%) with AF
<30 s
NR
Cotter et al.
(2013)
51 51.5 ± 13.9 54.9% Median 3 (2–4) Mean 229 ± 112 days
in patients with-
out AHRE
AF >2 min 13/51 (25.5%) Median 48 days
(0–154)
Ritter et al.
(2013)
60 Median 63
(48.5–72.0)
56.7% Median 4 (3–5) with-
out AHRE; me-
dian 4 (3–5) with
AHRE
Median 397 days
(337–504) with-
out AHRE; me-
dian 312 days
(242–397) with
AHRE
AF >2 min 10/60 (16.7%) Median 64 days
(1–556)
Etgen et al.
(2013)
22 60.0 without AF;
65.8 with AF
43.8% without
AF; 66.7%
with AF
NR 12 months AF >_6 min 6/22 (27.3%) Mean 152.8
Rojo-Martinez
et al. (2013)
101 67 46.5% NR 281 ± 212 days AF >2 min 34/101 (33.7%) Median 102 days
(26–240)
SURPRISE
(2014)
85 54.0 without AF;
66.9 with AF
58.0% without
AF; 44.4%
with AF
Median 3 without
AHRE; median 4
with AHRE
569 ± 310 days AF >2 min 18/85 (20.7%) 109 ± 48 days
CRYSTAL AF
(2014)
441 (208 ICM) 61.5 ± 11.3 63.5% NR 12 months AF >2 min 8.9% at 6 months;
12.4% at
12 months
Median 41 days
(14–84)
CRYSTAL AF
(2016)
48 (24 ICM)? 61.6 ± 11.4 ? NR 36 months AF >2 min 30% ?
Poli et al.
(2016)
74 66.4 ± 12.5 47% Median 5 (4–6) 12 months AF >2 min 21/74 (28.4%) at
6 months; 25/74
(33.8%) at
12 months
105 ± 135 days
Israel et al.
(2017)
123 65.0 ± 9.4 60.2% 4.5 ± 1.3 12.7 ± 5.5 months AF >_2 min 29/123 (23.6%) Average 3.6 months
Reinke et al.
(2018)
105 64.4 ± 12.6 56.2% Median 4 (3–6) ? AF >2 min 19/105 (18%) Median 217 days
(72.5–338)
Pedersen et al.
(2018)
105 Median 65.4
(27.1–80.8)
45.7% Median 4 (2–7) Median 381 days
(371–390)
AF >_2 min 7/105 (6.7%) Median 21 days
(5–146)
?, not reported; AF, atrial fibrillation; AHRE, atrial high-rate episode; ILR, implantable loop recorders; ICM, intracardiac monitor; NR, not recorded.
.....................................................................................................................................................................................................................
Table 3 Incidence of ILR-detected subclinical AF in patients at high risk of stroke
Study Number
of
patients
Mean age
(years)
% male Duration of follow-up Definition of AHRE Patients with AHRE Time to first
AHRE
ASSERT-II (2017) 273 73.9 ± 6.2 65.6% 16.3 ± 3.8 months AF including AFL and AT
>_5 min
90/256 (35.2%) 5.1 ± 5.5 months
REVEAL AF (2017) 446 71.5 ± 9.9 52.3% 22.5 ± 7.7 months AF >_6 min 29.3% at 18 months; 6.2%,
20.4%, 27.1%, 33.6%, and
40.0% at 1, 6, 12, 24, and
30 months
Median 123 days
(41–330)
PREDATE AF
(2017)
245 74.3 ± 7.7 58.8% 18 months; mean follow-up
451 ± 185 days
AF >_6 min 55/245 (22.4%) 141.3 ± 139.5 days
Philippsen et al.
(2017)
82 71 ± 4.0 63% Median 588 days (453–712) AF >_2 min 17/82 (20.7%); 14/82 (17%)
AF >_6 min
Median 91 days
(41–251)
Romanov et al.
(2018)
50 57.8 ± 8.3 88% >_24 months AF >_2 min 29/50 (58%) at 24 months;
16%, 40%, 50%, and 54% at
3, 6, 12, and 18 months
Median 4.8 months
AF, atrial fibrillation; AFL, atrial flutter; AHRE, atrial high-rate episode; ILR, implantable loop recorders.
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paroxysmal AF. Recent trials in anticoagulated AF patients reported
lower stroke rates in paroxysmal vs. non-paroxysmal AF patients
(SPORTIF,67 ARISTOTLE,68 and ENGAGE-AF69). A meta-analysis
combining data from >95 000 patients70 appears to confirm that
stroke risk may be slightly lower in patients with paroxysmal AF com-
pared with those with chronic AF.
Patients at high stroke risk
without atrial fibrillation do not
benefit from oral anticoagulation
Oral anticoagulation using either vitamin K antagonists such as warfa-
rin or non-vitamin K antagonist oral anticoagulants (NOACs) has
been tested in several conditions predisposing for stroke other than
AF usually without evidence for effectiveness.
Anticoagulants in survivors of a stroke
without atrial fibrillation
Conducted almost 20 years ago, the WARSS trial could not
detect a clinical benefit of warfarin [target international normal-
ized ratio (INR) 1.4–2.8] over 325 mg aspirin per day after a non-
cardioembolic ischaemic stroke in patients without AF within 2
years.71 In patients with a recent embolic stroke of undetermined
source, the NAVIGATE ESUS trial has been stopped in 2017 due
to no efficacy improvement of 15 mg rivaroxaban over 100 mg as-
pirin daily, with an increased risk of bleeding in patients random-
ized to rivaroxaban.72 A similar trial with dabigatran, the RE-
SPECT ESUS study, similarly reported no reduction in stroke
rates in patients randomized to dabigatran, with increased clini-
cally relevant major bleedings compared to aspirin.73
Anticoagulants in patients with other
neurological disorders
The CADISS trial tested warfarin vs. aspirin in patients with symp-
tomatic carotid and vertebral artery dissection.74 No difference was
detected between oral anticoagulation or single antiplatelet treat-
ment. The WASID trial compared warfarin (target INR 2.0–3.0) with
high-dose aspirin (1300 mg per day) in patients with transient ischae-
mic attack or stroke caused by a 50–99% stenosis of a major intracra-
nial artery.75 This study was stopped prematurely after 569 patients
because of a significantly higher bleeding rate without any benefit in
the warfarin arm.
Anticoagulation in patients with heart
failure, but without atrial fibrillation
The WARCEF trial showed no difference between long-term warfa-
rin and aspirin treatment in 2305 patients with a left ventricular ejec-
tion fraction below 35% and sinus rhythm.76 The primary composite
endpoint (ischaemic stroke, intracerebral haemorrhage, and death
from any cause) comprised 7.47 events per 100 patient-years in the
warfarin group and 7.93 in the aspirin group. COMMANDER-HF
confirmed that rivaroxaban, albeit at a lower dose than the dose ap-
proved for stroke prevention in AF, was not effective in prevention
of strokes compared with no anticoagulation in a similar heart failure
population.77
Risk of bleeding in patients
treated with oral anticoagulants
The benefit of oral anticoagulation in patients with AF can so far only
be achieved by exposing patients to an increased bleeding risk.72,78
Non-vitamin K antagonist oral anticoagulant treatment is associated
with a markedly lower rate of intracranial haemorrhage and lower
mortality than Vitamin K antagonist therapy,79 but the bleeding rate
on NOACs is still important (ca. 2% per year of exposure), both in
clinical trials79 and in patients exposed to NOACs under routine
care conditions.80–83 In summary, the bleeding rates associated with
different NOACs in real-world patients vary from 1.9% to 4.3% per
year of treatment. Absolute rates depend on patient characteristics
such as age. Notably, these findings on the rates of major bleeding
with NOACs are comparable with the major bleeding rates reported
in the pivotal randomized clinical trials.
The average atrial high-rate epi-
sodes burden is only a few hours
per year, and the majority of
patients with atrial high-rate epi-
sodes never receive a clinical diag-
nosis of atrial fibrillation
Current anticoagulation guidelines in non-valvular AF are supported
by studies in patients with ECG-documented AF episodes, whether
symptomatic or not.84,85 Clinical diagnosis of AF in patients with
AHRE was evaluated more than 10 years ago in the Ancillary MOST
substudy,7 performed in 312 patients included in the MOST study.86
The population was heterogeneous, and patients with previously
documented AF were not excluded. Selected patients had a pace-
maker implanted due to sinus node dysfunction but were in sinus
rhythm at randomization, and the analysis was retrospective and ob-
servational. During a median follow-up of 27 months, AHREs were
detected in 160 patients (51.3%). Twenty of these patients had AF
history documented before AHRE detection. Of the remaining 140
patients without previous AF, 36 (25.7%) had AF documented during
follow-up. Similar or lower rates of AF detection were found in the
ASSERT and ASSERT II studies.
Hence, although AHRE renders detection of ECG-documented
AF more likely, the majority (>75%) of patients with AHRE never de-
velop ECG-documented AF in the subsequent years, probably due to
the infrequent and short nature of AHRE episodes in most patients.
Stroke risk in atrial high-rate epi-
sode patients is lower than in
patients with paroxysmal atrial
fibrillation
There is a growing body of evidence on the stroke risk in patients
with AHREs. In the ASSERT study, the annual thromboembolic event
rate was 1.7% in patients with AHRE within 3 months after inclusion,
6 E. Bertaglia et al.
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compared with 0.7% in patients who did not show AHRE within
3 months after inclusion. These numbers are comparable to a recent
systematic review where patients with AHRE had an annual stroke
rate of 1.9%, compared with 0.9% in patients without AHRE.88
Recently, a subanalysis from ASSERT focused on the longest AHRE
episode found that only AHRE >24 h was associated with an in-
creased risk of stroke compared with absence of AHRE.87 This is
much lower than the stroke risk that can be expected in patients
with a similar stroke risk profile and ECG documented AF.
Interestingly, strokes occur equally during periods with and without
AHRE in patients with AHRE suffering a stroke.89 Furthermore, the
current licences of NOACs do not explicitly allow their use in
patients with AHRE. Thus, also in view of the bleeding risk associated
with anticoagulation, we do not know whether to use oral anticoagu-
lation in patients with AHRE.
Summary: equipoise for oral
anticoagulation in patients with
atrial high-rate episode
Most modern pacemakers, defibrillators, and cardiac resynchroni-
zation devices provide automated algorithms alerting to AHRE.
A growing body of clinical data supports the hypothesis that
AHREs are associated with an elevated risk of developing further
clinical AF and stroke, but the stroke risk is substantially lower
than in patients with ECG-detected AF, most likely due to the very
rare and short nature of AHRE episodes.90 In view of the small but
substantial risk of major bleeding in patients treated with oral
anticoagulants, including NOACs, there is currently no justifica-
tion for oral anticoagulation in patients with AHRE. Two ongoing
studies, NOAH-AFNET 691 and ARTESiA,92 will address the key
question of whether patients with AHRE benefit from oral antico-
agulation. ARTESiA (Apixaban for the Reduction of Thrombo-
Embolism in Patients With Device-Detected Sub-Clinical AF) aims
to enroll 4000 high-risk (CHA2DS2-VASc score >_3) participants
with permanent pacemakers, defibrillators, or resynchronization
device, and at least one AHRE episode of 6 min to 24 h duration
(atrial rate >175/min if an atrial lead is present).92 Patients will be
randomized to receive apixaban or aspirin. The primary efficacy
outcome is ischaemic stroke or systemic embolism; the primary
safety outcome is major bleeds. The NOAH-AFNET 6 study
(NOAC in patients with AHRE) trial is recruiting ca 3000 patients
aged >65 years with one additional CHA2DS2-VASc factor and
AHRE documented by CIED (>_170 b.p.m. atrial rate and >_6 min
duration).91 These patients will be randomized to edoxaban or
aspirin/placebo, depending on the indications for antiplatelet
therapy. The primary outcome parameter of NOAH-AFNET 6 is a
composite of stroke, systemic embolism, or cardiovascular death.
The results of these two trials have the potential to inform
future guidance on the management of patients with atrial
arrhythmias detected by implantable devices. Until these trials
have reported, treatment with oral anticoagulants should be
limited to rare individual decisions in patients with AHRE, but
without ECG-diagnosed AF, to avoid the substantial bleeding risk
on anticoagulation.
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